Premium
Half‐life extended factor VIII for the treatment of hemophilia A
Author(s) -
Tiede A.
Publication year - 2015
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.12929
Subject(s) - medicine , polyethylene glycol , factor ix , surgery , engineering , chemical engineering
Summary Prophylactic infusion of factor VIII ( FVIII ) prevents joint bleeding and other hemorrhages in patients with hemophilia A. Conventional FVIII concentrates have a short half‐life, with an average of about 12 h in adults, ranging in individual patients between 6 and 24 h, and even shorter in younger children. Therefore, effective prophylaxis requires frequent intravenous injection, usually three times per week or every other day. Several technologies are currently under investigation to extend the half‐life of FVIII , including Fc fusion (Eloctate, Elocta, efmoroctocog alfa), addition of polyethylene glycol (turoctocog alfa pegol [N8‐ GP ], BAY 94‐9027, BAX 855), and a single‐chain construct ( CSL 627). This review summarizes characteristics of products in clinical development and discusses their potential benefits.